Open Access
Med Sci (Paris)
Volume 35, Number 4, Avril 2019
Page(s) 289 - 291
Section Le Magazine
Published online 30 April 2019
  1. Iffland PH. 2nd, Crino PB. Focal cortical dysplasia : gene mutations, cell signaling, and therapeutic implications. Annu Rev Pathol 2017 ; 12 : 547–571. [CrossRef] [PubMed] [Google Scholar]
  2. Blumcke I, Thom M, Aronica E, et al. The clinicopathologic spectrum of focal cortical dysplasias : a consensus classification proposed by an ad hoc task force of the ILAE diagnostic methods commission. Epilepsia 2011 ; 52 : 158–174. [CrossRef] [PubMed] [Google Scholar]
  3. Marsan E, Baulac S. Mechanistic target of rapamycin (mTOR) pathway, focal cortical dysplasia and epilepsy. Neuropathol Appl Neurobiol 2018 ; 44 : 6–17. [CrossRef] [PubMed] [Google Scholar]
  4. Bar-Peled L, Chantranupong L, Cherniack AD, et al. A tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science 2013 ; 340 : 1100–1106. [Google Scholar]
  5. Ishida S, Picard F, Rudolf G, et al. Mutations of DEPDC5 cause autosomal dominant focal epilepsies. Nat Genet 2013 ; 45 : 552–555. [Google Scholar]
  6. Baldassari S, Picard F, Verbeek B, et al. The landscape of epilepsy-related GATOR1 variants. Genet Med 2018 ; 21 : 398–408. [CrossRef] [PubMed] [Google Scholar]
  7. Knudson AG, Jr.. Mutation and cancer : statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971 ; 68 : 820–823. [CrossRef] [Google Scholar]
  8. Magerus-Chatinet A, Rieux-Laucat F. Le modèle du two-hit de Knudson s’applique aux maladies auto-immunes. L’exemple du syndrome lymphoproliferatif avec auto-immunité (ALPS). Med Sci (Paris) 2011; 27 : 107–9. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  9. Ribierre T, Deleuze C, Bacq A, et al. Second-hit mosaic mutation in mTORC1 repressor DEPDC5 causes focal cortical dysplasia-associated epilepsy. J Clin Invest 2018 ; 128 : 2452–2458. [CrossRef] [PubMed] [Google Scholar]
  10. Lim JS, Kim WI, Kang HC, et al. Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy. Nat Med 2015 ; 21 : 395–400. [CrossRef] [PubMed] [Google Scholar]
  11. French J, Friedman D. The evolving landscape of epilepsy neuropathology. Lancet Neurol 2018 ; 17 : 202–203. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.